objective To investigate the seroprevalence of Sarcocystosis in the local communities of Pangkor and Tioman islands, Malaysia, by using antigenic recombinant surface antigens 2 and 3 from Sarcocystis falcatula (rSfSAG2 and rSfSAG3) as the target proteins via Western blot and ELISA assays.
Introduction
Sarcocystis is an apicomplexan intracellular protozoan parasite that causes sarcocystosis in infected hosts. Sarcocystis spp. have a heterogeneous life cycle involving intermediate and definitive hosts. The definitive host (predator) gets infected upon consuming the intermediate host (prey) harbouring Sarcocystis. Sarcocystis undergoes sexual stages in the host's intestine and is then excreted with host faeces. The life cycle is completed when the intermediate host consumes food contaminated with sporocysts/oocysts, which undergo asexual stages and then invade muscle tissue in the intermediate host [1] .
Infection in humans can lead to intestinal or muscular sarcocystosis. For intestinal sarcocystosis, humans act as the definitive host when consuming infected raw or undercook meat such as pork and beef. Muscular sarcocystosis infection occurs when human become an accidental intermediate host by ingesting sporocysts/ oocysts from contaminated water or food. Human sarcocystosis is considered a zoonotic infection [2] .
Recent acute muscular sarcocystosis outbreaks in the Pangkor and Tioman Islands in Malaysia have caused almost 200 travellers to experience two series of distinct symptoms -relapsing fever and myalgia; and asthenia, headache and cough. In addition, facial swelling was reported in a few of the affected individuals [3] . Sarcocystis nesbitti was reported to be responsible for these outbreaks [4, 5] .
Sarcocystis nesbitti has a snake-primate life cycle [6] [7] [8] in which human is an aberrant intermediate host. Water is a potential medium for transmission of Sarcocystis [9] . In Tioman Island, most of the water supplies originate from untreated environment sources such as gravity feed and tube wells [10] . Although treated water is supplied to the communities in Pangkor Island, there was a report on temporary supply breakdown before the outbreak [11] .
Currently, the gold standard for the diagnosis of human muscular sarcocystosis is muscular biopsy (histologic examination and/or PCR), although this invasive procedure is rarely done due to difficulties in obtaining written consent. The standard practices of diagnosis are based on clinical signs and travel history. Molecular techniques such as PCR on blood containing merozoites are hardly successful in detection because it is only feasible for acute infection [12] . While serodiagnosis of sarcocystosis remain experimental, Sarcocystis fusiformis antigen has been used in ELISA and IFAT [13, 14] . CDC has been using Sarcocystis neurona merozoite-derived antigens in Western blot [11] . The disadvantage of using the whole parasite is that it requires in vitro culture of the parasites, which can be difficult, time consuming, costly and hazardous. The use of recombinant proteins has advantages. These proteins are more specific, easy to mass-produce and economical.
In this research study, the target proteins for the development of the diagnostic assay for sarcocystosis are the surface antigens (SAGs). Like Toxoplasma gondii, many glycosylphosphatidylinositol (GPI)-anchored proteins known as surface antigens are found on the surface of S. neurona [15, 16] and they are orthologue to SRS (SAG1-related sequences) superfamily proteins of T. gondii [17] . SAGs are structurally related but antigenically distinct. SAGs of T. gondii are involved in host cell attachment, invasion, immune modulation and/or virulence [18] [19] [20] [21] . In S. neurona, surface proteins Sn14 and Sn16 are involved in interactions with the host cell membrane during the invasion [22] and are known to exhibit immunogenic characteristic, and thus serve as potential markers for developing diagnostic tests [15, 16] . A serodiagnostic test for human sarcocystosis will be useful for confirming infection, screening for asymptomatic infections, surveillance and epidemiological studies. This is important for effective clinical management and implementation of prevention measures.
Methods

Generation of SfSAG2 and SfSAG3
Amino-terminal signal peptide and carboxyl-terminal GPI anchor sequences of SfSAGs were predicted using SignalP 2.1 Server and PredGPI predictor; and removed from all expression constructs in E. coli. SfSAGs were amplified using extracted DNA/cDNA from Sarcocystis falcatula Stiles ATCC 50701 and nested primers containing a restriction enzyme BamHI cut site ( Table 1) . The PCR reaction (25 ll) was carried out using GoTaq Flexi DNA Polymerase (Promega) and DNA/cDNA template (4 ll). PCR denaturing step was at 94°C for 2 min, 30 cycles of denaturation at 94°C for 30 s, annealing (Table 1) for 30 s and elongation at 72°C for 90 s. Then, final elongation step at 72°C for 7 min and held at 16°C. Nested PCR was performed using nested 2 primers (Table 1) using the same reaction mixture (4 ll of PCR product from nested 1) followed by the same PCR steps. 
Cloning
The PCR products were cloned into the pGEM-T vector (Promega) and transformed into competent E. coli TOP10 cells. Purified pGEMT-SfSA2, pGEMT-SfSAG3 and pRSET A vector were digested with RE BamHI at 37°C for 2 h. The digested pRSET A vector was treated with calf intestine alkaline phosphatise and ligated with the target insert. Recombinant plasmid with the correct orientation was transformed into E. coli BL21(DE3) pLysS strain. The plasmids were sent to MyTACG Bioscience Enterprise (Malaysia) for bi-directional sequencing and analysed by BLAST. Evaluation of human sera against purified rSfSAG2 and rSfSAG3 via Western blot rSfSAGs were tested in Western blot against serum of volunteers [Pangkor (n = 100); Tioman (n = 98)], non-Sarcocystis parasitic infections [amoebiasis (n = 3), cysticercosis (n = 3), filariasis (n = 3), malaria (n = 23), toxocariasis (n = 1), toxoplasmosis (n = 17)] and healthy donors (n = 100). PVDF membrane strip with 70-100 ng blotted purified recombinant protein was blocked overnight at 4°C with 5% skimmed milk/TBS. Then, incubation of serum sample (1:250 dilution in 2.5% skimmed milk) for 2 h at room temperature, followed by incubation with biotin-labelled goat anti-human IgM + IgG + IgA (1:2500 dilution in 2.5% skimmed milk/TBS) for 1 h, streptavidinalkaline phosphatase (1:2500 dilution in 2.5% skimmed milk/TBS) for 1 h, and finally NBT/BCIP substrate for colour development. Three time washes with 0.2% TBS-T were performed after every incubation steps. Selected sera were also tested with total lysate antigen (TLA) of S. falcatula and BT cell lines for comparison.
Expression of recombinant proteins
Evaluation of human sera against purified rSfSAG2 and rSfSAG3 via ELISA Protein (10 lg/ml in 100 ll) was coated on Nunc MaxiSorp flat-bottom 96 well microtitre plate (Thermo Scientific) using 0.05 M sodium bicarbonate buffer (pH 9.6) and incubated overnight at 4°C. Blocking (1% BSA/PBS) was performed for 2 h at 37°C, followed by serum sample (1:80 dilution in 1% BSA/PBS) incubation for 1 h at 37°C. Then, HRP-labelled goat anti-human IgM + IgG + IgA (1:2500 dilution in 1% BSA/PBS) incubation was carried on for 1 h at 37°C and finally incubation of TMB for 30 min in dark. The reaction was stopped by adding 2N sulphuric acid. Five washes with 0.1% PBS-T were performed after every incubation step. The absorbance of samples was measured at 450 nm using a microplate reader. Samples were run in duplicates. The cut-off value was set at M N + 2r of the healthy donor sera group (M N : mean absorbance, r: standard deviation). Samples with absorbance higher than M N + 2r were considered positive.
Result
BLAST analysis
BLAST results of the nucleotide sequences of SfSAG2 and SfSAG3 were 93% and 96% identical to the reference sequence of S. falcatula SAG2 (Accession number: GQ851953.1) and SAG3 (Accession number: GQ851956.1) respectively. BLAST results of the protein sequences were 86% and 91% identical to reference sequences of S. falcatula SAG2 (Accession number: ADG26776.1) and SAG3 (Accession number: ADG26779.1), respectively.
Evaluation of rSfSAG2 and rSfSAG3 probed with antirSfSAGs and anti-SfTLA antibodies by Western blot Antigenicity of purified rSfSAGs was evaluated by probing with anti-rSfSAGs and anti-SfTLA harvested from infected Balb/c mice sera. Figure 1 shows a single band of rSfSAG2 (~15 kDa) and rSfSAG3 (~26 kDa) reacted positively when probed with anti-rSfSAG2 and antirSfSAG3 respectively. The same detection was observed when rSfSAGs were probed with anti-SfTLA. No band was detected for negative control anti-BTTLA.
Evaluation of SfTLA probed with anti-rSfSAGs antibodies by Western blot
To confirm that the source of rSfSAGs was S. falcatula, rSfSAGs was evaluated by probing SfTLA with antirSfSAGs harvested from infected Balb/c mice sera. Figure 2 shows that a single band of native SfSAG2 (~12 kDa) and SfSAG3 (~23 kDa) reacted positively when probed with anti-rSfSAG2 and anti-rSfSAG3 respectively. No band detected anti-pRSET A protein. The SfSAGs in protein cocktail of TLA were untagged native proteins (without hexa-histidine-tag), hence the difference in molecular weight (the size of the N-terminal tag was~3 kDa).
Evaluation of purified rSfSAG2 and rSfSAG3 by Western blot and ELISA using volunteer and patient sera
The purified rSfSAGs were evaluated in Western blot and ELISA assays by using 348 sera of categories: (i) local communities of Pangkor and Tioman Islands, (ii) nonSarcocystis parasitic infections and (iii) healthy donors. Serum from S. nesbitti-infected patient could not be obtained; hence no true positive serum was available during this study. However, sera from mice infected with rSfSAGs from S. falcatula were used as positive control. In Western blot analysis, none of the sera from this study reacted with rSfSAG2. For rSfSAG3, 34% (34/100) of volunteer sera from Pangkor Island and 75.5% (74/98) of volunteer sera from Tioman Island reacted positively.
Also, 30% (15/50) of non-Sarcocystis parasitic infection patient sera reacted positively, where low reactivity of closely related parasite T. gondii was observed [13% (2/17)]. However, high positive reactivity of malariainfected patients was observed [47.8% (11/23)]. Other parasitic infections were amoebiasis, cysticercosis, filariasis and toxocariasis. For healthy donor sera, 8% (8/100) of the sera showed positive reactivity ( Figure 3) . Evaluation of rSfSAG3 with volunteer and patient sera by using Western blot analysis is summarised in Table 2. In the ELISA assay, none of the sera from this study reacted with rSfSAG2. However, for rSfSAG3, 37% (37/ 100) of volunteer sera from Pangkor Island and 43.8% (43/98) of volunteer sera from Tioman Island reacted positively.
Additionally, 28% (14/50) of non-Sarcocystis parasitic infection patient sera reacted positive. The high percentage of seropositivity was obtained because samples of five toxoplasmosis-infected patients and five malaria-infected samples reacted positive. Only 10% (10/100) of healthy donor sera reacted positively. The evaluation of rSfSAG3 with volunteer and patient sera by using ELISA assay is summarised in Table 2 .
Evaluation of total lysate antigen against positive volunteer sera in Western blot
Positive sera from selected volunteers and healthy donors were evaluated by Western blot against SfSTLA to confirm the reactivity of positive sera against the TLA of the parasite. Selected sera were chosen for verification. Figure 4 shows a single band of SfSAG3 with a size of~2 3 kDa reacted positively when probed with positive sera from volunteers. No band was detected for negative control sera. In addition, no band was detected at 12 kDa (SfSAG2) when probed with positive sera (a). A similar profile was repeated on TLA of BT cell cultures, where none of the sera reacted to BTTLA (b).
Discussion rSfSAGs
Previously, DNA of S. nesbitti was successfully isolated from water samples in Tioman Island Shahari et al [9] ., However, PCR using SAGs gene-specific primers failed to amplify SAGs in the DNA. Thus, S. falcatula was chosen as the source of DNA template for the production of SfSAGs. The availability of this parasite and its DNA sequences on GenBank facilitated the amplification of SfSAGs genes. Unlike S. falcatula, S. neurona SAGs genes are patented [23] . Hence, only genes from S. falcatula were used in this study. The amplified SfSAG2 and SfSAG3 have 93% and 96% identity with the nucleotide and 86% and 91% identity with the amino acid sequences of SfSAGs reference sequences in GenBank, respectively. This is usual because SfSAGs have extensive polymorphisms in their exons that may result in deletion or insertion of codons [16, 24, 25] and polymorphic sequences would be expected to have lower sequence coverage with the reference sequences in GenBank.
Assessment of rSfSAGs in Western blot and ELISA using human sera
Western blot is often used as a confirmation test. For example, in HIV serodiagnoses, positive sera by ELISA are reconfirmed via Western blot [26] . ELISA is a quantitative method that can be used to determine antibody titre in sera. It requires less serum to work with, which is important for optimisation of serodiagnosis. Although ELISA is a method of choice for large screening in epidemiology studies, it is less specific since the tendency of producing false-positive result may lead to inaccuracy in the assessment, whereas in Western blot, false-positive result is less likely to happen [27] . In addition, Western blot provides easy detection by direct visualisation and gives a clear distinction between positive and control samples [28] .
The purified rSfSAGs were confirmed to originate from S. falcatula (Figures 1b and 2) . Therefore, rSfSAGs were evaluated for antigenicity against the serum of volunteers from the two islands, non-Sarcocystis-infected patients and healthy donors. Healthy donor sera used in this study were archived samples used in previous studies for serodiagnosis assessments of malaria [29, 30] and toxoplasmosis [31] . Sensitivity and specificity of the rSfSAGs could not be evaluated in this study. The absence of true positive S. nesbitti-infected patient serum is a limiting factor. Another limitation is the origin of the samples: in Tioman Island, the samples were collected mainly from the hot spots (northwest/east coast) of the island and thus do not represent the total island's population. There are many potential Sarcocystis species yet to be discovered capable of infecting humans [1, 32] . The true prevalence of Sarcocystis species inhabiting both islands is still unknown. Western blot and ELISA analyses show no reactivity between rSfSAG2 and human sera although this antigen was reactive when it was probed with anti-SfSAG2 and anti-SfTLA (Figures 1 and 2) . Although the sera used in the analysis of S. falcatula TLA were strongly reactive towards SfSAG3, no band was detected at~12 kDa for SfSAG2 (Figure 4) . Therefore, it is postulated that the SfSAG2 was less immunodominant compared with SfSAG3.
rSfSAG3
In the Western blot analysis, sera from Tioman Island exhibited higher reactivity against rSfSAG3 than sera from Pangkor Island indicating that the communities of Tioman Island face a higher risk of infection. This may be due to the utilisation of an untreated source as the main water source [10] , whereas Pangkor Island is supplied with chlorinated [33] . Additionally, the long period of exposure might contribute to the differences since this outbreak continued over several years, whereas Pangkor's outbreak was just once and very localised. High seroprevalence in both islands (Table 2) suggested previous exposure to Sarcocystis.
The reactivity of rSfSAG3 against sera from Pangkor Island in Western blot and ELISA was similar. However, sera from Tioman Island exhibited higher reactivity in Western blot than ELISA (Table 2) . This difference may be due to the large number of borderline positives or negatives. Similar observations were reported in previous studies where sensitivity and specificity for Plasmodium knowlesi MSP-1 33 and MSP-1 42 in Western blot were higher than ELISA [29] , and a high sensitivity of MSP-3 was observed in ELISA compared to Western blot [30] .
Sarcocystosis and toxoplasmosis
A previous study reported moderate similarity (<25%) of S. neurona SAGs to T. gondii TgSAGs [15] . Also, S. falcatula SAGs are orthologues to S. neurona SAGs with >95% nucleotide sequence identity [16] . In this study, low reactivity of SfSAG3 with closely related parasite T. gondii was observed in the Western blot assay ( Table 2 ). Absence of reactivity was observed when rSfSAGs was probed with serum from a mouse infected with T. gondii via Western blot (result not shown) despite the similarity in the SAGs of the parasite species. In addition, absence of cross-reactivity of S. fusiformis total antigen with serum from patients infected with T. gondii has been reported previously [14] . Moreover, more than half of the positive serum samples from Tioman Island were tested positive with commercial Novalisa T. gondii IgG and IgM ELISA kits from NovaTec. A similar finding was previously seen in Malaysian donors to have antibodies to Sarcocystis and Toxoplasma [34] . Toxoplasma gondii can be acquired through exposure to contaminated soil [35] and animal hosts [36] . Co-infection with Sarcocystis species and T. gondii are common in animals such as marine mammals and horses [37, 38] . Hence, co-infection of these two parasites in human is possible. Higher reactivity in ELISA may again be due to borderline activity where the absorbance value was just above the cut-off value as observed in this study, hence the false-positive result ( Table 2 ).
Sarcocystosis and malaria
It is possible for a malarial patient to be infected with Sarcocystis, since it is abundant in nature and infection is through ingestion of sarcocysts/sporocysts in contaminated food or water [1] . Interestingly, a previous study on parasitic infections in Pangkor Island showed absence of malarial and intestinal sarcocystosis, indicating improvements in facilities and sanitation [33] . However, diagnosis of intestinal sarcocystosis was only based on the presence of sporocysts in faecal samples and serology assessment was not conducted.
Considering the limitation to obtain the anti-serum of animal infected with human Plasmodium species, no reactivity was observed when rSfSAGs probed with serum from a mouse infected Plasmodium berghei (a rodent malarial parasites) via Western blot (result not shown). Previously, monoclonal antibody raised from recombinant apical membrane antigen 1 (AMA1) of Plasmodium vivax showed cross-reactivity with homologues proteins from P. berghei, P. cynomolgi, P. knowlesi, and P. falciparum via immunofluorescence assays [39] . Polyclonal antibodies raised from P. berghei in a mouse could provide a preliminary result of any potential cross-reactivity between these two coccidian parasites. BLAST analysis of SfSAGs nucleotide and amino acid sequences was conducted revealing no significant similarity with any protein in Plasmodium species (phylum: apicomplexa), hence, eliminating the possibility of cross-reactivity with Plasmodium species. Therefore, co-infection might be the probable reason why the majority of malarial serum samples reacted with rSfSAG3 (Table 2) .
Sarcocystosis and other parasitic infections
No cross-reactivity was observed in the sera of patients with toxocariasis. However, discrepancy in Western blot and ELISA analyses was observed in the sera of amoebiasis, cysticercosis and filariasis patients (Table 2) . Similar BLAST analysis was conducted thus eliminating potential cross-reactivity. However, BLAST analysis is based on the existing nucleotide sequences deposited in the database. Cross-reactivity with other parasites remains inconclusive. Hence more samples are needed to test for crossreactivity. However, there is a possibility of co-infection between Sarcocystis species and the parasites above. Coinfection among parasites is common. Although co-infection of Sarcocystis with other parasites tested in this study is rarely studied, co-infection involving protozoa and helminthic infections such as Ascaris, Entamoeba, Schistosoma, Trichinella, Trichuris and hookworms have been reported in South East Asia [40, 41] . In Peninsular Malaysia, co-infection of intestinal sarcocystosis and intestinal helminthiasis was reported in an Orang Asli [42] . Co-infection can occur especially if the risk factors are similar. Poor sanitation and personal hygiene practices could potentially increase the risk factors. Preventive measures such as personal hygiene, proper sanitation and safe food preparation should be practised. Authorities may provide proper facilities such as treated water and an improved public health infrastructure to substantially reduce the rate of infection.
Assessment of TLA against positive volunteer sera in Western blot
Western blot was used to determine the antigenicity of the positive sera reacting with the native protein in TLA of S. falcatula. All sera which reacted with rSfSAG3 in the Western blot were positive with TLA of S. falcatula. A distinct single band at~23 kDa likely to be SfSAG3 was detected (Figure 4) . A similar result was observed when S. fusiformis TLA was used in Western blot, where the~23 kDa band was the most reactive [14] . Local communities may not be infected by S. falcatula, but by S. nesbitti or unknown Sarcocystis species. Therefore, there is a potential of cross-reactivity of antigens among different species of Sarcocystis, hence serodiagnosis for sarcocystosis can be developed.
Although a single band can be obtained using SfTLA, some of the antigens may cross-react with antigens from other organisms. Increasing the quantity of the parasite by large-scale culture requires a significant amount of time, while E. coli is easily mass produced. In addition, the anti-rSfSAGs recognised its native proteins (Figure 2) . Therefore, these results suggest that the rSfSAGs proteins produced in this study maintained their epitopes and can be used as effective candidates for diagnosis of sarcocystosis.
Conclusion
This is the first study reporting a seroprevalence of sarcocystosis in Pangkor and Tioman Islands, Malaysia. Higher seroprevalence of sarcocystosis among local communities was observed in Tioman Island compared with Pangkor Island via Western blot. SfSAG3 was shown to be more immunodominant than SfSAG2. SfSAG3 appeared to be suitable candidates for serodiagnosis of Sarcocystis infection at the genus level. Validation of the serodiagnosis tests with the sarcocystosis patients' sera should be conducted in order to confirm infection, asymptomatic screening, surveillance and epidemiological studies. In addition, further evaluation is needed to assess the antigenic properties of SfSAG3, i.e. epitopes characterisation. Infection and immunisation studies should be done in the animal model using potential peptide epitopes.
